Introduction

Oncology Letters

1792-1074 1792-1082

D.A. Spandidos

10.3892/ol.2025.14963

OL-29-5-14963

Articles

Prognostic value of HER2 expression in cervical adenocarcinoma: A retrospective cohort study

Qing

1 2 Yin

Zhuomin

2 Li

Yueqi

1 2 Zhu

Xiu

3 Lou

Hanmei

2 Ni

Juan

1The Second School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, Zhejiang 310053, P.R. China 2Department of Gynecological Oncology, Zhejiang Cancer Hospital, Hangzhou, Zhejiang 310022, P.R. China 3Department of Pathology, Zhejiang Cancer Hospital, Hangzhou, Zhejiang 310022, P.R. China

Correspondence to: Professor Juan Ni or Professor Hanmei Lou, Department of Gynecological Oncology, Zhejiang Cancer Hospital, 1 Banshan East Road, Hangzhou, Zhejiang 310022, P.R. China, E-mail: juejue3149@163.com, E-mail: louhm@zjcc.org.cn

05 2025

05 03 2025

29 5

217

15102024 30012025

2025

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

Human epidermal growth factor receptor 2 (HER2) is an important therapeutic target in various types of cancer, although the prognostic value and therapeutic potential of HER2 in cervical adenocarcinoma are still underexplored. The present study aimed to examine the association between HER2 expression levels and prognosis in cervical adenocarcinoma, offering new insights into targeted therapies for HER2-expressing cervical adenocarcinoma. A total of 179 patients with cervical cancer who received surgery were included, and HER2 status in surgical specimens of the included patients were assessed using two classification methods: Immunohistochemistry (IHC) alone and traditional combined IHC/fluorescence in situ hybridization (FISH). IHC alone was used to categorize patients into the HER2 zero expression (IHC 0) and HER2 expression (IHC 1+, 2+ and 3+) groups, while traditional combined IHC/FISH classified the HER2 expression as negative (IHC 0 and 1+ or IHC 2+/FISH-) or positive (IHC 3+ or IHC 2+/FISH+). Kaplan-Meier survival analysis and log-rank tests were used to assess the patients' survival prognosis. A Cox proportional hazards regression model was used to identify independent prognostic factors. The HER2 expression rate was 44.1% (79/179) according to IHC alone, while 5.0% (9/179) were classified as HER2-positive according to the traditional method. HER2 expression was significantly associated with advanced International Federation of Gynecology and Obstetrics stages, higher rates of lymph node metastasis, vascular or perineural invasion, elevated cancer antigen 125 levels and increased recurrence rate (P<0.05). Moreover, HER2 expression was significantly associated with shorter progression-free survival (PFS) time [51.02±2.75 vs. 56.01±2.22 months; hazard ratio (HR), 0.559; 95% confidence interval (CI), 0.313–0.998; P=0.049]. Additionally, programmed death-ligand 1 expression levels were significantly higher in HER2-expressing patients who died (P=0.039). When HER2 status was assessed using the traditional combined IHC/FISH method, HER2 positivity was significantly associated with poorer PFS time (36.44±7.85 vs. 55.17±1.78 months; HR, 0.125; 95% CI, 0.03033–0.5156; P=0.004). In conclusion, classification of HER2 status in patients with cervical adenocarcinoma using IHC alone may provide a promising method for predicting patient outcomes and optimizing therapeutic strategies to improve treatment efficacy.

HER2 cervical adenocarcinoma IHC prognosis

Key Project of Medicine and Health Major Science and Technology Plan of Zhejiang Province

WKJ-ZJ-2020

This study was supported by the Key Project of Medicine and Health Major Science and Technology Plan of Zhejiang Province (grant no. WKJ-ZJ-2020).

Introduction

Cervical cancer is the fourth most prevalent malignancy among women globally (1). Adenocarcinoma, which accounts for 10–25% of cervical cancer cases, typically exhibits distinct cytological features on cytology smears. These include uniform polygonal cells arranged in flat sheets and glandular structures, granular cytoplasm, indistinct cell boundaries and round to oval nuclei with prominent nucleoli (2). Moreover, due to its higher propensity for metastasis and poorer prognosis, adenocarcinoma also presents significant challenges in patient management (3,4). The current treatment strategy for cervical adenocarcinoma primarily involves surgery for early stage disease and chemoradiotherapy for advanced-stage disease. The overall 5-year survival rate for early stage cases is 70–90%, while the survival rate for advanced-stage cases is typically <20% (5). Despite advancements in immunotherapy that have provided therapeutic breakthroughs for patients with cervical cancer, the prognosis of cervical adenocarcinoma remains poor (6). There is an urgent need to explore new targeted therapies to improve patient survival. Therefore, it is necessary to study new biomarkers to improve prognostic accuracy and promote the further development of targeted therapies.

Human epidermal growth factor receptor 2 (HER2), a member of the EGFR family, serves a pivotal role in tumor growth and progression by inhibiting apoptosis and promoting angiogenesis and metastasis (7). HER2 upregulation occurs in various types of cancer (8), and numerous studies (9–12) have indicated that HER2 protein expression levels are a poor prognostic factor in malignant tumors and are associated with tumor sensitivity to chemotherapy and biological therapy. Particularly in breast and gastric cancer, HER2 has been extensively studied and successfully applied as a therapeutic target in clinical practice (13–15). However, in cervical cancer, especially in the subtypes of cervical adenocarcinoma and squamous cell carcinoma, the role and clinical significance of HER2 remains controversial. Studies (16,17) have shown that HER2 expression levels are higher in cervical adenocarcinoma compared with those in squamous cell carcinoma, particularly in advanced and high-risk patients, suggesting that HER2 may be involved in the pathological progression of adenocarcinoma. Other studies (17–19) have suggested that HER2 could be a valuable therapeutic target in cervical adenocarcinoma, especially for patients with advanced disease or disease progression. Although some studies (20–22) have found that HER2 expression levels are associated with a poor prognosis, significant variations in HER2 expression levels and prognostic significance across studies could be attributed to factors such as sample size, and detection methods such as immunohistochemistry (IHC)/fluorescence in situ hybridization (FISH). Moreover, in previous studies (17,23), the expression of HER2 in cervical adenocarcinoma was low according to the traditional assessment method of combined IHC/FISH, and its association with prognosis in cervical adenocarcinoma remains unclear.

In recent years, anti-HER2-drug conjugates (ADCs) have garnered attention for their ability to target HER2-expressing cancer cells and improve therapeutic outcomes (24). The prevalence of IHC 1+ and 2+/FISH-HER2 expression in gynecological tumors has become an important focus for clinicians. Research has demonstrated that in the C018 cervical cancer cohort study, the range of patients benefiting from RC48 anti-HER2 therapy expanded to include IHC 1+, 2+ and 3+ groups. Notably, an objective response rate (ORR) of up to 50% was observed in IHC 1+ patients (25). This underscores the importance of more precise classification of HER2 expression levels, which is essential for guiding personalized treatment strategies for cervical cancer.

At present, traditional HER2 detection methods have the disadvantage of low detection rates, which limits treatment options for HER2 patients with low expression and thus affects prognosis (26). Standalone IHC could provide the sensitivity of HER2 status detection, with the advantages of being fast, simple, cost-effective and highly specific, making it more effective in assessing clinical prognosis, and will help more accurately evaluate the therapeutic effects of HER2-targeted drugs (27). However, there is a lack of research investigating the association between standalone IHC and clinical prognosis. The present study aimed to investigate HER2 expression levels in patients with cervical adenocarcinoma, with a particular focus on IHC 1+ and 2+/FISH-cases, and to evaluate its prognostic significance, as well as its association with programmed death-ligand 1 (PD-L1) expression levels.

Patients and methods <sec> <title>Patients

The present study retrospectively analyzed HER2 status via IHC in 179 female patients with cervical adenocarcinoma undergoing radical surgery (including 10 patients who received neoadjuvant chemotherapy before surgery) between January 2018 and November 2020 at Zhejiang Cancer Hospital (Hangzhou, China). The present study was conducted in accordance with the Declaration of Helsinki with the approval of the Medical Ethics Committee of Zhejiang Cancer Hospital (approval no. IRB-2023-656), and all patients provided written informed consent for publication of their data.

Patients included in the present study were required to meet the following criteria: Aged between 18 and 70 years, with pathologically confirmed cervical adenocarcinoma, who received radical surgery, with complete clinical and pathological data, and who signed an informed consent form at admission (which included consent for their samples to be used for research). Exclusion criteria included patients lost to follow-up or those with insufficient tissue samples for HER2 testing.

Data collection and follow up

Patients' age, clinical stage, pathological diagnosis, tumor size, lymph vascular space invasion (LVSI), extent of invasion, lymph node metastasis status, whether neoadjuvant therapy was administered before surgery, HER2 expression status, pre-treatment carbohydrate antigen 19-9 (CA19-9), pre-treatment cancer antigen 125 (CA-125), recurrence status, recurrence time, survival status, last follow-up time and time of death were recorded. Progression-free survival (PFS) and overall survival (OS) were followed up through outpatient visits and telephone interviews. The data cut-off date was June 2024.

Clinical characteristics [including age, International Federation of Gynecology and Obstetrics (FIGO) stage, tumor size, depth of invasion, vascular invasion or perineural invasion, pre-treatment CA19-9 values and pre-treatment CA-125 values] and prognostic factors (metastasis, recurrence and survival data) were analyzed in the IHC alone group. Additionally, the expression ratio between PD-L1 and HER2 in patients with cervical adenocarcinoma who died was analyzed. OS and PFS were measured from pathological diagnosis to death from any cause and to the first disease progression, respectively. The clinical data were obtained from the medical records of Zhejiang Cancer Hospital and tissue samples were obtained from the pathology archives of the hospital.

HER2 status analysis

According to the guidelines (23) for HER2 testing in gastric cancer and other malignancies, HER2 1+ and HER2 2+/FISH- are defined as negative, while HER2 2+/FISH+ and HER2 3+ are defined as positive. Targeted therapy is recommended for patients with HER2-positive status (28). To broaden the scope of treatment and improve patient prognosis, the present study population was divided into groups. Patient tumor samples were tested using IHC and FISH methods. The detection results were used to classify patients by HER2 status into the following groups based on IHC alone and the traditional combined IHC/FISH method: i) IHC alone, patients were divided into the HER2 zero expression (IHC 0) group and the HER2 expression (IHC 1+, 2+ and 3+) group; and ii) traditional combined IHC/FISH classification, patients were categorized as HER2-negative (IHC 0, IHC 1+ or IHC 2+/FISH-) or HER2-positive (IHC 3+ or IHC 2+/FISH+).

IHC

Paraffin-embedded samples were fixed with 10% neutral formalin for 24 h at room temperature. IHC was performed on 3-µm thick sections obtained from formalin-fixed, paraffin-embedded tissue blocks. The immunohistochemistry images were captured using a light microscope. PD-L1 and HER2 were targeted using specific primary antibodies. The gold standard for detecting PD-L1 expression is IHC (29), which utilizes the high specificity of antibody-antigen binding to display the location and intensity of antigen-antibody binding through histochemical techniques, thereby detecting the expression levels of PD-L1 on the surface of tumor cells or immune cells. In the present study, PD-L1 expression levels were assessed using slides stained for PD-L1 22C3 (catalog number M3666; Dako, Agilent Technologies, Inc.) and the combined positive score (CPS) method was applied for evaluation. The procedure was performed according to the manufacturer's instructions. CPS was calculated as: (Number of PD-L1-positive tumor cells + number of PD-L1-positive immune cells)/total number of viable tumor cells ×100. A CPS threshold of ≥1 was used to determine PD-L1 positivity (30). CPS=0 indicated that PD-L1 expression was negative (Fig. S1) with no brown staining observed in tumor cells or immune cells. By contrast, when PD-L1 was positively expressed in tumor cells or immune cells, partial brown staining was observed (Fig. S2). This indicates a certain level of PD-L1 expression in the tumor microenvironment, providing a reference for the evaluation of immunotherapy. In addition, the present study adhered to American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guidelines (31) for gastric cancer to establish HER2 IHC scoring criteria. These criteria were defined as follows: 0, no staining or <10% of tumor cell membranes stained; 1+, ≥10% of tumor cells with faint or barely perceptible membrane staining, with only part of the membrane stained; 2+, ≥10% of tumor cells with weak to moderate complete, basolateral or lateral membrane staining; and 3+, ≥10% of tumor cells with strong complete, basolateral or lateral membrane staining. Based on HER2 expression scoring standards in gastric and gastroesophageal adenocarcinoma, HER2 staining was categorized as: 0, negative; 1+, negative; 2+, equivocal; and 3+, positive (32). Cases with equivocal HER2 upregulation (2+) results were further analyzed using FISH (33).

FISH

FISH tests were conducted using the Vysis PathVysion HER2 DNA Probe Kit (Abbott Pharmaceutical Co. Ltd.), according to the manufacturer's protocol. The dual-color FISH method, involving two labeled DNA probes, was performed on sections cut from the same tissue microarray block. The LSI HER2 probe, which spans the entire HER2 gene, was labeled in Spectrum Orange, while the CEP17 probe (chromosome-17 centromere probe for chromosome 17 enumeration) was labeled in Spectrum Green. These probes hybridized to the a satellite DNA located at the centromere of chromosome 17 (17p11.1-q11.1). For analysis, two separate fields comprising ≥20 cells each were counted. The HER2 signal ratio was calculated by tallying red (HER2 gene) and green (chromosome 17) signals in preselected tumor areas. Tumor cells from the same sites analyzed by IHC were typically assessed for signal counts. Images were captured using an ECLIPSE 80i (Nikon Corporation) fluorescence microscope with a PlanFluor (Nikon Corporation) 100X oil objective and a double band-pass filter enabling simultaneous visualization of green and red colors.

IHC and FISH interpretation and quality control

Representative images of different levels of HER2 expression using IHC and FISH are shown in Figs. 1 and 2, respectively, and data presented in Tables I and II. For quality control of IHC/FISH analysis, two pathologists with >5 years of experience independently interpreted the results. In cases of disagreement and the inability to reach a consensus, a third senior reviewer made the final judgment.

Statistical analysis

Statistical analyses were conducted using SPSS (version 25; IBM Corp.). Clinical and pathological characteristics were compared using the χ² test or Fisher's exact test as appropriate. Survival analysis was performed using the Kaplan-Meier method and comparisons were made using log-rank tests. Multivariate analysis was performed using the Cox proportional hazards regression model to identify independent prognostic factors. All reported P-values were two-sided. P<0.05 was considered to indicate a statistically significant difference.

Results <sec> <title>HER2 expression levels in cervical adenocarcinoma

The present study included 179 patients with cervical adenocarcinoma who underwent radical surgery, and HER2 expression was evaluated through IHC and FISH results (Figs. 1 and 2). A novel classification method specifically designed to evaluate HER2 expression using IHC alone was utilized (Fig. 3). In the IHC alone group, the expression rates of IHC 1+, 2+ and 3+ were 27.4% (49/179), 12.8% (23/179) and 3.9% (7/179), respectively, which indicated that 44.1% of samples exhibited HER2 expression. In the traditional combined IHC/FISH method group, there were 7 HER2 3+ cases and 23 HER2 2+ cases (data not shown). After FISH testing, only 2 of the 23 cases were FISH-positive. Therefore, the total number of HER2-positive patients was 9, accounting for only 5% of included patients.

Association of HER2 expression and clinical factors in the IHC group

There were 100 patients with HER2 zero expression and 79 patients with HER2 expression. As shown in Table III, the age distribution between the HER2 zero expression group and the HER2 expression group was generally similar and showed no statistically significant difference among patients with cervical adenocarcinoma who underwent radical surgery. However, the mean age at onset was 49.75±11.40 years for patients in the HER2 zero expression group and 47.97±10.72 years for those in the HER2 expression group among patients with cervical adenocarcinoma who underwent radical surgery (Table III). HER2 expression was significantly associated with advanced FIGO stages (P=0.001) and higher recurrence rates (P=0.032). Among the tumor markers, abnormal pre-treatment CA-125 levels were significantly associated with HER2 expression (P=0.023), whereas pre-treatment CA19-9 levels did not reach statistical significance (P=0.15).

Patients in the HER2 zero expression group exhibited a survival rate of 57.7% and a mortality rate of 46.7%, compared with a survival rate of 42.3% and a mortality rate of 53.3% for the HER2 expression group, suggesting a trend towards improved prognosis for patients without HER2 expression, although this was not statistically significant (P=0.266). When excluding the 10 patients who had received neoadjuvant chemotherapy, postoperative pathological findings indicated that HER2 expression was significantly associated with vascular or perineural invasion (P=0.029) and lymph node metastasis (P=0.002), with no significant differences observed in tumor size or invasion depth.

Association between HER2 expression and prognosis

IHC alone and combined IHC/FISH both indicated that patients with HER2 expression experienced significantly poorer PFS times compared with those without HER2 expression. In the IHC alone group, the PFS time was 56.01±2.22 months for the HER2 IHC 0 group and 51.02±2.75 months for the HER2 expression group, with a statistically significant difference when compared [hazard ratio (HR), 0.559; 95% confidence interval (CI), 0.313–0.998; P=0.049; Fig. 4]. Kaplan-Meier survival curves were used to evaluate OS based on HER2 status, which demonstrated that the OS time of the patients with HER2 expression was slightly lower compared with that of the patients without HER2 (Fig. 5). Specifically, the OS was 69.47±1.93 months for the HER2 zero expression group and 58.47±2.22 months for the HER2 expression group, although this difference did not reach statistical significance (HR, 0.657; 95% CI, 0.318–1.356; P=0.255).

In the traditional method group, which employed combined IHC/FISH, the PFS time was 55.17±1.78 months for the HER2-negative group, compared with 36.44±7.85 months for the HER2-positive group, showing a statistically significant difference (HR, 0.125; 95% CI, 0.03033–0.5156; P=0.004; Fig. 6). The present study showed that the risk of poor survival in HER2-negative patients was significantly lower compared with that of HER2-positive patients, with an HR of 0.1250, which indicated that the survival risk in the HER2-negative group was only 12.5% of that in the HER2-positive group. Therefore, HER2 negativity was associated with an improved prognosis. Kaplan-Meier survival curves comparing HER2 positivity and OS indicated an OS time of 68.06±1.60 months for the HER2-negative group and 54.11±7.48 months for the HER2-positive group, with no statistically significant difference observed (OS; HR, 0.628; 95% CI, 0.114–3.465; P=0.593; Fig. 7).

Association between HER2 and PD-L1 expression in cervical adenocarcinoma

The association between HER2 expression and PD-L1 expression in 37 cases of cervical adenocarcinoma with fatal outcomes was analyzed (Table IV). Among these cases, 21 (56.8%) exhibited PD-L1 expression. The data suggested a statistically significant association between HER2 expression and increased levels of PD-L1 expression (χ², 4.259; P=0.039). Furthermore, the overlap in HER2 and PD-L1 expression was found to be 40.5%. Specifically, among the 16 PD-L1-negative patients, 6 cases (37.5%) showed HER2 expression. By contrast, among the 21 PD-L1-positive patients, 15 cases (71.4%) showed HER2 expression. The proportion of HER2-positive patients in the PD-L1-positive group was higher compared with that in the PD-L1-negative group.

Multivariate analysis of factors associated with disease progression in patients

In the multivariate Cox regression analysis of factors influencing disease progression in 179 patients with cervical adenocarcinoma after radical surgery, factors such as LVSI, depth of invasion, tumor size, pre-treatment levels of CA19-9 and CA-125, HER2 expression, age, staging and lymph node metastasis were included. These factors were selected as they are commonly considered relevant in cancer prognosis and disease progression (34). Patient prognosis was significantly associated with LVSI (P=0.003), but not HER2 expression (P=0.401), age (P=0.520), depth of invasion (P=0.284), tumor size (P=0.261) or the tumor markers CA19-9 (P=0.654) and CA-125 (P=0.630) (Table V). The confidence intervals for staging and lymph node metastasis were excessively wide.

Discussion

Although numerous studies have reported that HER2 expression may impact the prognosis of patients with various types of cancer (35,36), data specific to cervical cancer remains limited. According to the latest National Comprehensive Cancer Network guidelines (version 1, 2024), HER2 IHC testing is recommended for patients with advanced recurrent or metastatic cervical cancer (37). However, a standardized protocol for HER2 testing and interpretation in cervical cancer has yet to be established. In gynecological tumors, HER2 testing often references guidelines for breast cancer, which report very low rates of high HER2 expression and gene amplification in cervical cancer, with rates of 5.7 and 1.2%, respectively (38). In the present study, 179 patients with cervical adenocarcinoma were evaluated using breast cancer guidelines, which identified only 9 HER2-positive cases. Based on the traditional combined IHC/FISH classification, the HER2 positivity rate was 5%. Meanwhile, using the ASCO/CAP gastric cancer guidelines, IHC alone has shown higher rates of high HER2 expression in cervical cancer, at 27.0% (38). In the present study, when assessed by gastric cancer guidelines, IHC alone (1+ to 3+) identified 72 cases of low HER2 expression (40.2%), with an overall HER2 expression rate of 44.1%. In a study by Shi et al (17), involving 209 patients with cervical adenocarcinoma, 123 were identified as HER2-positive, resulting in a positivity rate of 58.9%. Among these, 100 patients (47.8%) exhibited low HER2 expression. The study also observed higher HER2 expression in gastric-type adenocarcinoma compared with ordinary adenocarcinoma, which was potentially associated with poor prognosis. These findings were consistent with the present results. Additionally, a previous study indicated that HER2 staining in cervical adenocarcinoma frequently exhibits incomplete membrane patterns (such as basolateral or U-shaped) in 12.2% of cases (15/123) and intratumoral staining heterogeneity in 17.1% of cases (21/123), resembling patterns observed in gastric and gastroesophageal adenocarcinomas (17). Given these similarities, the HER2 assessment criteria that aligned with those used for gastric cancer were adopted in the present study.

HER2, a receptor tyrosine kinase, exerts its effects through several key biological pathways. First, the PI3K/AKT/mTOR pathway serves a pivotal role in cell survival, proliferation and metabolic regulation, with its aberrant activation frequently observed in various types of cancer (39). The MAPK signaling pathway contributes to tumor development and progression by promoting cell proliferation, differentiation and survival (40). Additionally, the JAK2/STAT3 pathway facilitates uncontrolled cancer cell growth, resistance to apoptosis and regulation of cell survival. These pathways are not only integral to tumor biology but also serve as potential therapeutic targets (41). With increasing focus on HER2 expression in cervical cancer, the use of ADCs in metastatic HER2-expressing cervical cancer has emerged as a key area of interest. Current clinical trial data on ADCs in cervical cancer treatment shows promising outcomes for patients. The open-label phase II study, DESTINY-PanTumor02 (42), aimed to evaluate the efficacy and safety of trastuzumab deruxtecan (T-DXd; 5.4 mg/kg) as a second-line treatment for HER2-expressing solid tumors. In the cervical cancer cohort, 40 patients were enrolled and T-DXd demonstrated significant antitumor activity, with an ORR of 50%. Additionally, the RC48-C018 study included a cervical cancer cohort of patients with HER2-expressing recurrent or metastatic disease who had undergone at least one prior line of treatment. As of October 2023, 25 patients with cervical cancer were enrolled, with 22 being evaluable for efficacy. The ORR was 36.4% (including 1 complete response), the disease control rate was 86.4%, the median duration of response was 5.52 months and the median PFS time was 4.37 months (25). The advent of ADCs represents a novel treatment strategy for cervical cancer, making the detection of HER2 (especially IHC 1+ and 2+/FISH-) particularly important.

In recent years, the emergence of immunotherapy has brought new hope to some patients with advanced cervical cancer. PD-L1 is a critical co-stimulatory molecule in immune responses and exhibits a high expression rate in cervical cancer (43). This characteristic suggests that PD-L1 may serve an important role in the immune regulation of cervical cancer. Additionally, numerous studies have shown a potential synergy between the expression levels of HER2 and PD-L1. Oki et al (44) found that in gastric cancer cells, HER2 expression levels were positively correlated with PD-L1 expression levels. Among patients with HER2 3+ status, 72.4% demonstrated high levels of PD-L1 expression. Furthermore, when HER2 expression was downregulated using siRNA, PD-L1 protein levels were significantly reduced, indicating that HER2 signaling pathways might directly or indirectly regulate PD-L1 expression. Similarly, Chaganty et al (45) proposed that a combination of anti-HER2 therapy and anti-programmed cell death protein 1/PD-L1 therapy could be a potential strategy to improve therapeutic outcomes in breast cancer. In the present study, data from 37 patients who died were analyzed. The results showed that among the 21 PD-L1-positive patients, 15 (71.4%) also demonstrated HER2 expression, indicating a high level of co-expression between the two markers. Furthermore, the overlap in HER2 and PD-L1 expression was found to be 40.5%, and the present results demonstrated a statistically significant association between HER2 expression and PD-L1 expression levels (χ², 4.259; P=0.039), suggesting a potential association between these two markers in the tumor microenvironment. These findings provide an important basis for further investigation into the synergistic effects of HER2 and PD-L1 and their potential application in dual-targeted therapy. This observation was consistent with previous studies in gastric, esophageal and esophago-gastric cancer, which supported dual HER2 and PD-L1 targeting, showing clinical benefits (46,47). Such evidence offers a foundation for more individualized treatment strategies for patients with cervical cancer with dual HER2 and PD-L1 expression.

Univariate analysis in the present study demonstrated a significant association between HER2 expression in patients with cervical adenocarcinoma and adverse clinicopathological characteristics, such as advanced FIGO stage, lymph node metastasis, presence of vascular cancer thrombus, nerve invasion and abnormal CA-125 levels. Patients with HER2 expression typically exhibited multiple poor prognostic factors, contributing to an overall worse prognosis. The present study indicated HER2 to be a potentially key biomarker for prognostic evaluation in patients with cervical adenocarcinoma. However, the multivariate analysis did not show consistent results. The absence of statistical significance between HER2 expression and disease progression may be attributed to insufficient sample size or collinearity among variables, potentially masking its effect. Although HER2 failed to demonstrate independent prognostic significance, this does not exclude its potential role, and further investigations with larger sample sizes are essential to validate these findings. Numerous studies have demonstrated that adverse clinicopathological factors significantly impact the prognosis of patients with cervical cancer. These high-risk factors include lymph node metastasis, vascular or perineural invasion and FIGO staging (48,49). The present study suggests that HER2 expression may be associated with a poorer prognosis. Martinho et al conducted a pathological study using IHC techniques to analyze HER2 expression in cancer tissues from 229 patients with cervical cancer, including 194 adenocarcinomas and 35 squamous carcinomas (20). Univariate analysis suggested a notable but non-significant trend toward an association between HER2 positivity and poor prognosis (P=0.07). Kaplan-Meier curve analysis further associated HER2 upregulation with adverse prognosis (P=0.014). Multivariate analysis confirmed metastasis and HER2 upregulation as independent prognostic factors for patients with cervical cancer (20). In the present analysis, PFS time for patients in the HER2 zero expression group was increased compared with that of patients with HER2 expression, with an HR of 0.559, indicating a ~44.1% reduction in the risk of disease progression or death. The 95% CI (0.313–0.998) and a P-value of 0.049 further supported the statistical significance of this observation.

In summary, patients with HER2 expression exhibited worse PFS time compared with those in the HER2 zero expression group. Moreover, OS time for patients in the HER2 zero expression group appeared improved compared with that for patients with HER2 expression, with an HR of 0.656, indicating a potential 34.4% reduction in mortality risk. However, the 95% CI (0.318–1.356) and a non-significant P-value of 0.255 suggested uncertainty in these results. Although the OS in HER2 zero expression shows a better trend compared to HER2 expression, it did not reach statistical significance, and longer-term studies may elucidate significant differences. Therefore, HER2 status holds significant implications for assessing disease progression and could potentially serve as a pivotal biomarker for treatment and prognosis monitoring in cervical adenocarcinoma.

The present study had several limitations that warrant consideration. First, the analysis of HER2 expression in the samples was conducted retrospectively. Due to the extended time between surgery and sample collection, samples that originally expressed HER2 may have lost the protein over time, leading to insufficient staining. Therefore, the actual HER2 expression rate may be higher. Second, due to the lack of established HER2 assessment guidelines specifically for cervical adenocarcinoma, the present study, similar to others (42), referenced guidelines originally developed for breast or gastric cancer. HER2 assessment standards can differ significantly across such different cancer types (50). Third, the present study was limited by its retrospective design, and insufficient available data and sample size, which made conducting sensitivity analyses challenging and resulted in the absence of sensitivity analysis. Larger-scale studies or clinical trials are needed to validate and generalize these findings.

In summary, the present study evaluated HER2 IHC expression in patients with cervical adenocarcinoma using gastric cancer assessment criteria. HER2 expression was analyzed based on both traditional and newly established standalone IHC classification methods. The findings underscore the association between HER2 expression and adverse prognostic factors in patients undergoing radical surgery for cervical adenocarcinoma. HER2-positive patients experienced poorer PFS times, emphasizing the critical role of early HER2 status assessment in guiding treatment decisions for cervical adenocarcinoma. Tumor patients expressing HER2 who have died may also exhibit higher PD-L1 expression levels, and the combined expression of these markers could help physicians develop personalized treatment strategies. This approach holds promise for predicting patient outcomes and optimizing therapeutic strategies to improve treatment efficacy.

Future research will explore the pathological characteristics of cervical cancer in greater depth, particularly focusing on the association between HER2 expression and cervical squamous cell carcinoma. This effort aims to develop tailored treatment approaches that could ultimately enhance survival rates and improve the quality of life for patients with cervical cancer.

Supplementary Material

Supporting Data

Acknowledgements

Not applicable.

Availability of data and materials

The data generated in the present study may be requested from the corresponding author.

Authors' contributions

QX, ZY, YL, XZ and JN were responsible for data collection, processing, and interpretation. QX was responsible for methodology, software, formal analysis and manuscript writing. ZY partook in formal analysis and investigation. YL performed formal analysis. XZ contributed to the study design and data analysis, as well as to the processing of data images. JN contributed to study conception and design, and reviewed and edited the manuscript. HL undertook study conceptualization, resources, project administration, funding acquisition and supervision. All authors read and approved the final manuscript. QX and JN confirm the authenticity of all the raw data.

Ethics approval and consent to participate

The present study was conducted in accordance with the Declaration of Helsinki with the approval of the Medical Ethics Committee of Zhejiang Cancer Hospital (Hangzhou, China; approval no. IRB-2023-656). Patients signed an informed consent form at admission, which included consent for their samples to be used for research.

Patient consent for publication

Patients provided written informed consent for publication of their data.

Competing interests

The authors declare that they have no competing interests.

Abbreviations

HER2

human epidermal growth factor receptor 2

IHC

immunohistochemistry

FISH

fluorescence in situ hybridization

PD-L1

programmed death-ligand 1

ADC

antibody-drug conjugate

PFS

progression-free survival

overall survival

References 1

Sung

Ferlay

Siegel

Laversanne

Soerjomataram

Jemal

Bray

Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

CA Cancer J Clin712092492021

10.3322/caac.21660

33538338

Albadri

Salomão

Metastatic prostate adenocarcinoma to cervical lymph nodes: An unusual diagnosis on fine-needle aspiration biopsy

J Am Soc Cytopathol102312382021

10.1016/j.jasc.2020.08.009

32950433

Saida

Sakata

Tanaka

Ochi

Ishiguro

Sakai

Takahashi

Satoh

Minami

Clinical and MRI characteristics of uterine cervical adenocarcinoma: Its variants and mimics

Korean J Radiol203643772019

10.3348/kjr.2018.0458

30799567

Gadducci

Guerrieri

Cosio

Adenocarcinoma of the uterine cervix: Pathologic features, treatment options, clinical outcome and prognostic variables

Crit Rev Oncol Hematol1351031142019

10.1016/j.critrevonc.2019.01.006

30819439

Quinn

Benedet

Odicino

Maisonneuve

Beller

Creasman

Heintz

Ngan

Pecorelli

Carcinoma of the cervix uteri. FIGO 26th Annual Report on the results of treatment in gynecological cancer

Int J Gynaecol Obstet95(Suppl 1)S43S1032006

Xie

Kong

Zhao

Zhang

Luo

Chen

Immune checkpoint inhibitors in cervical cancer: Current status and research progress

Front Oncol129848962022

10.3389/fonc.2022.984896

36387196

Fang

Yun

Liu

Cai

Antibody-drug conjugates targeting the human epidermal growth factor receptor family in cancers

Front Mol Biosci98478352022

10.3389/fmolb.2022.847835

35295841

Zhan

Dong

Tang

Wang

Xiong

Analysis of HER2 gene amplification and protein expression in esophageal squamous cell carcinoma

Med Oncol299339402012

10.1007/s12032-011-9850-y

21318736

Slamon

Clark

Wong

Levin

Ullrich

McGuire

Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene

Science2351771821987

10.1126/science.3798106

3798106

Seshadri

Firgaira

Horsfall

McCaul

Setlur

Kitchen

Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group

J Clin Oncol11193619421993

10.1200/JCO.1993.11.10.1936

8105035

Jørgensen

Hersom

HER2 as a prognostic marker in gastric cancer-a systematic analysis of data from the literature

J Cancer31371442012

10.7150/jca.4090

22481979

Park

Yun

Park

Kim

Cho

Sohn

Jeon

Kim

Yoo

HER-2/neu amplification is an independent prognostic factor in gastric cancer

Dig Dis Sci51137113792006

10.1007/s10620-005-9057-1

16868827

Shimozaki

Fukuoka

Ooki

Yamaguchi

HER2-low gastric cancer: Is the subgroup targetable?

ESMO Open91036792024

10.1016/j.esmoop.2024.103679

39178538

Harbeck

Advances in targeting HER2-positive breast cancer

Curr Opin Obstet Gynecol3055592018

10.1097/GCO.0000000000000431

29194077

Bang

Van Cutsem

Feyereislova

Chung

Shen

Sawaki

Lordick

Ohtsu

Omuro

Satoh

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial

Lancet3766876972010

10.1016/S0140-6736(10)61121-X

20728210

Kunos

Fabian

Piecoro

Napier

Miller

Ueland

Human epidermal growth factor receptor 2 expression in women with uterine cervix adenocarcinoma from Appalachian Kentucky

Front Oncol139483482023

10.3389/fonc.2023.1126426

36761943

Shi

Shao

An analysis of HER2 amplification in cervical adenocarcinoma: Correlation with clinical outcomes and the International Endocervical Adenocarcinoma Criteria and Classification

J Pathol Clin Res786952021

10.1002/cjp2.184

33089969

Friedman

D'Souza

Bello Roufai

Tinker

de Miguel

Gambardella

Goldman

Loi

Melisko

Oaknin

Targeting HER2-mutant metastatic cervical cancer with neratinib: Final results from the phase 2 SUMMIT basket trial

Gynecol Oncol1811621692024

10.1016/j.ygyno.2023.12.004

38211393

Liu

Zhuo

Wang

Lin

Pan

Song

A metastatic cervical adenocarcinoma patient carrying HER2 G292R achieved complete response upon pyrotinib treatment

Onco Targets Ther14483348362021

10.2147/OTT.S321655

34556997

Martinho

Silva-Oliveira

Cury

Barbosa

Granja

Evangelista

Marques

Miranda-Gonçalves

Cardoso-Carneiro

de Paula

HER family receptors are important theranostic biomarkers for cervical cancer: Blocking glucose metabolism enhances the therapeutic effect of HER inhibitors

Theranostics77177322017

10.7150/thno.17154

28255362

Dang

Jiao

Prognosis of HER2 over-expressing gastric cancer patients with liver metastasis

World J Gastroenterol18240224072012

10.3748/wjg.v18.i19.2402

22654433

Zhou

Expression of HER2 and BRCA1 correlates with prognosis in patients with breast cancer after radiotherapy: A Case-control study

Cancer Biother Radiopharm376036112022

33112672

Van Cutsem

Bang

Feng-Yi

Lee

Jiao

Chong

López-Sanchez

Price

Gladkov

HER2 screening data from ToGA: Targeting HER2 in gastric and gastroesophageal junction cancer

Gastric Cancer184764842015

10.1007/s10120-014-0402-y

25038874

Wang

Gong

Wang

Wei

Peng

Wang

Zhou

Liu

Disitamab vedotin (RC48) plus toripalimab for HER2-expressing advanced gastric or gastroesophageal junction and other solid tumours: A multicentre, open label, dose escalation and expansion phase 1 trial

EClinicalMedicine681024152024

10.1016/j.eclinm.2023.102415

38235421

Lingying

Zhang

Sun

Zhang

Huang

Guo

Miao

Evaluation of the effectiveness and safety of disitamab vedotin For HER2-expressing recurrent cervical cancer after progression on platinum-based treatment-a single-arm, multicenter, open-label, phase II clinical study

Int J Gynecological Cancer34(Suppl 1)A6.1A62024

Nicolò

Boscolo Bielo

Curigliano

Tarantino

The HER2-low revolution in breast oncology: Steps forward and emerging challenges

Ther Adv Med Oncol15175883592311528422023

10.1177/17588359231152842

36844387

Schildhaus

Immunohistochemistry-based predictive biomarkers for lung cancer

Pathologe4121312020(In German)

10.1007/s00292-020-00750-7

31989233

Swain

Miles

Kim

Semiglazov

Ciruelos

Schneeweiss

Loi

Monturus

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): End-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study

Lancet Oncol215195302020

10.1016/S1470-2045(19)30863-0

32171426

Kim

Chung

PD-L1 Testing in Non-small cell lung cancer: Past, present, and future

J Pathol Transl Med531992062019

10.4132/jptm.2019.04.24

31042863

Huang

Ding

Guo

Gong

Zhao

Sui

Chen

Liu

Comparison of three FDA-approved diagnostic immunohistochemistry assays of PD-L1 in triple-negative breast carcinoma

Hum Pathol10842502021

10.1016/j.humpath.2020.11.004

33221342

Bartley

Washington

Colasacco

Ventura

Ismaila

Benson

IIICarrato

Gulley

Jain

Kakar

HER2 testing and clinical decision making in gastroesophageal adenocarcinoma: Guideline from the college of american pathologists, american society for clinical pathology, and the american society of clinical oncology

J Clin Oncol354464642017

10.1200/JCO.2016.69.4836

28129524

Vakiani

HER2 testing in gastric and gastroesophageal adenocarcinomas

Adv Anat Pathol221942012015

10.1097/PAP.0000000000000067

25844677

Hoang

Sahin

Ordòñez

Sneige

HER-2/neu gene amplification compared with HER-2/neu protein overexpression and interobserver reproducibility in invasive breast carcinoma

Am J Clin Pathol1138528592000

10.1309/VACP-VLQA-G9DX-VUDF

10874886

Zhou

Chen

Yan

Lou

Postoperative clinicopathological factors affecting cervical adenocarcinoma: Stages I–IIB

Medicine (Baltimore)97e93232018

10.1097/MD.0000000000009323

29480826

Dieci

Miglietta

Griguolo

Guarneri

Biomarkers for HER2-positive metastatic breast cancer: Beyond hormone receptors

Cancer Treat Rev881020642020

10.1016/j.ctrv.2020.102064

32622272

Sawaki

Ohashi

Omuro

Satoh

Hamamoto

Boku

Miyata

Takiuchi

Yamaguchi

Sasaki

Efficacy of trastuzumab in Japanese patients with HER2-positive advanced gastric or gastroesophageal junction cancer: A subgroup analysis of the Trastuzumab for Gastric Cancer (ToGA) study

Gastric Cancer153133222012

10.1007/s10120-011-0118-1

22179434

Abu-Rustum

Yashar

Arend

Barber

Bradley

Brooks

Campos

Chino

Chon

Crispens

NCCN Guidelines^® Insights: Cervical cancer, version 1.2024

J Natl Compr Canc Netw21122412332023

10.6004/jnccn.2023.0062

38081139

Itkin

Garcia

Straminsky

Adelchanow

Pereyra

Haab

Bardach

Prevalence of HER2 overexpression and amplification in cervical cancer: A systematic review and meta-analysis

PLoS One16e02579762021

10.1371/journal.pone.0257976

34591928

Zhang

Jiang

Zhu

Sun

Huang

Zhou

Zheng

Wang

PI3K/AKT/mTOR signaling pathway: An important driver and therapeutic target in triple-negative breast cancer

Breast Cancer315395512024

10.1007/s12282-024-01567-5

38630392

Coussy

El Botty

Lavigne

Fuhrmann

Briaux

de Koning

Dahmani

Montaudon

Morisset

Combination of PI3K and MEK inhibitors yields durable remission in PDX models of PIK3CA-mutated metaplastic breast cancers

J Hematol Oncol13132020

10.1186/s13045-020-0846-y

32087759

Maniaci

Giurdanella

Chiesa Estomba

Mauramati

Bertolin

Lionello

Mayo-Yanez

Rizzo

Lechien

Lentini

Personalized treatment strategies via integration of gene expression biomarkers in molecular profiling of laryngeal cancer

J Pers Med1410482024

10.3390/jpm14101048

39452555

Meric-Bernstam

Makker

Oaknin

Banerjee

González-Martín

Jung

Ługowska

Manso

Manzano

Efficacy and safety of trastuzumab deruxtecan in patients With HER2-expressing solid tumors: Primary results from the DESTINY-PanTumor02 Phase II Trial

J Clin Oncol4247582024

10.1200/JCO.23.02005

37870536

Enwere

Kornaga

Dean

Koulis

Phan

Kalantarian

Köbel

Ghatage

Magliocco

Lees-Miller

Doll

Expression of PD-L1 and presence of CD8-positive T cells in pre-treatment specimens of locally advanced cervical cancer

Mod Pathol305775862017

10.1038/modpathol.2016.221

28059093

Oki

Okano

Saeki

Umemoto

Teraishi

Nakaji

Ando

Zaitsu

Yamashita

Sugiyama

Protein expression of programmed Death 1 Ligand 1 and HER2 in gastric carcinoma

Oncology933873942017

10.1159/000479231

28910818

Chaganty

BKR

Qiu

Gest

Ivan

Calin

Weiner

Fan

Trastuzumab upregulates PD-L1 as a potential mechanism of trastuzumab resistance through engagement of immune effector cells and stimulation of IFNγ secretion

Cancer Lett43047562018

10.1016/j.canlet.2018.05.009

29746929

Alsina

Arrazubi

Diez

Tabernero

Current developments in gastric cancer: From molecular profiling to treatment strategy

Nat Rev Gastroenterol Hepatol201551702023

10.1038/s41575-022-00703-w

36344677

Valkema

Mostert

Lagarde

Wijnhoven

BPL

van Lanschot

JJB

The effectivity of targeted therapy and immunotherapy in patients with advanced metastatic and non-metastatic cancer of the esophagus and esophago-gastric junction

Updates Surg753133232023

10.1007/s13304-022-01327-0

35836094

Pinto

PJJ

Chen

Santos Neto

Faloppa

De Brot

Guimaraes

APG

Baiocchi

Prognostic factors in locally advanced cervical cancer with pelvic lymph node metastasis

Int J Gynecol Cancer322392452022

10.1136/ijgc-2021-003140

35256409

Gai

Wang

Meng

Kou

Liu

Clinicopathological factors influencing the prognosis of cervical cancer

J BUON242912952019

30941983

Abrahao-Machado

Scapulatempo-Neto

HER2 testing in gastric cancer: An update

World J Gastroenterol22461946252016

10.3748/wjg.v22.i19.4619

27217694

Figure 1.

Representative images of human epidermal growth factor receptor 2 status assessed by immunohistochemistry for scores (A) 0, (B) 1+, (C) 2+ and (D) 3+. Scale bar, 200 µm.

Figure 2.

Human epidermal growth factor receptor 2 status assessed by fluorescence in situ hybridization for (A) signal ratio <2.0 and (B) signal ratio ≥2.0.

Figure 3.

Distribution of patient numbers and detection rates across different HER2 expression levels (IHC 0, 1+, 2+ and 3+) assessed using IHC alone. HER2 zero expression (IHC 0) was the most common (100 cases, 55.9%), followed by HER2 1+ (49 cases, 27.4%), HER2 2+ (23 cases, 12.8%) and HER2 3+ (7 cases, 3.9%), indicating a relatively high proportion of positive HER2 expression in the present study cohort. HER2, human epidermal growth factor receptor 2; IHC, immunohistochemistry.

Figure 4.

Kaplan-Meier estimates for PFS according to HER2 status assessed by IHC alone. The IHC alone patients were stratified into the HER2 zero expression (IHC 0) and HER2 expression (IHC 1+, 2+ or 3+) groups. The PFS time in the HER2 zero expression group was significantly improved compared with that in the HER2 expression group (HR,0.559; P=0.049), indicating that HER2 expression was associated with an increased risk of progression. PFS, progression-free survival; HER2, human epidermal growth factor receptor 2; HR, hazard ratio; IHC, immunohistochemistry.

Figure 5.

Kaplan-Meier estimates for OS according to HER2 status assessed by IHC alone. The IHC alone patients were stratified into the HER2 zero expression (IHC 0) and HER2-expression (IHC 1+, 2+ or 3+) groups. Patients in the HER2 zero expression group exhibited improved OS times compared with those with HER2 expression; however, the difference did not reach statistical significance (HR, 0.657; P=0.255). OS, overall survival; HER2, human epidermal growth factor receptor 2; HR, hazard ratio; IHC, immunohistochemistry.

Figure 6.

Kaplan-Meier estimates for PFS and according to HER2 status assessed by the traditional combined IHC/FISH method. Patients were divided into the following groups: HER2-negative (IHC 0, IHC 1+ or IHC 2+/FISH-) or HER2-positive (IHC 3+ or IHC 2+/FISH+) assessed by the traditional combined IHC/FISH method. HER2-negative patients demonstrated significantly improved PFS times compared with HER2-positive patients (HR, 0.125; P=0.004). PFS, progression-free survival; HER2, human epidermal growth factor receptor 2; HR, hazard ratio; IHC, immunohistochemistry; FISH, fluorescence in situ hybridization.

Figure 7.

Kaplan-Meier estimates for OS according to HER2 status assessed by traditional combined IHC/FISH. Patients were divided into the following groups: HER2-negative (IHC 0, IHC 1+ or IHC 2+/FISH-) or HER2-positive (IHC 3+ or IHC 2+/FISH+) assessed by the traditional combined IHC/FISH method. Although HER2-negative patients show a numerically improved OS time compared with HER2-positive patients, the difference was not statistically significant (HR, 0.628; P=0.593). OS, overall survival; HER2, human epidermal growth factor receptor 2; HR, hazard ratio; IHC, immunohistochemistry; FISH, fluorescence in situ hybridization.

Table I.

Description of representative images of HER2 expression using IHC.

IHC status, score	Characteristics of IHC	IHC results
0	The cells appear blue, with no significant membrane staining observed in the glandular cells.	Fig. 1A
1+	The cells in the glandular structures show slight staining.	Fig. 1B
2+	Some glandular structures exhibit an incomplete membranous staining pattern (basolateral or ‘U-shaped’).	Fig. 1C
3+	The membranous staining of glandular cells is relatively complete, displaying a pattern that encircles the glands.	Fig. 1D

Table II.

Description of representative images of HER2 2+ using FISH.

Category	HER2/CEP17 signal ratio	FISH results
Non-amplification	<2.0	Fig. 2A
Amplification	≥2.0	Fig. 2B

HER2, human epidermal growth factor receptor 2; IHC, immunohistochemistry; FISH, fluorescence in situ hybridization.

Table III.

Association between HER2 status and characteristics in 179 cases in the HER2 zero expression (n=100) and HER2 expression (n=79) groups.

A, Total patient cohort

Variables	HER2 zero expression	HER2 expression	χ²	P-value
No. of patients	100	79
Age, n (%)			1.735	0.188
≤60 years	83 (53.9)	71 (46.1)
>60 years	17 (68.0)	8 (32.0)
FIGO stage, n (%)			10.116	0.001
I–IIB	78 (63.9)	44 (36.1)
III–IV	22 (38.6)	35 (61.4)
Recurrence status, n (%)			4.581	0.032
No progression	80 (60.6)	52 (39.4)
Progression	20 (42.6)	27 (57.4)
Survival status, n (%)			1.237	0.266
Survival	86 (57.7)	63 (42.3)
Death	14 (46.7)	16 (53.3)
Pre-treatment CA19-9 levels, n (%)			2.072	0.15
Normal	69 (59.0)	48 (41.0)
Abnormal	26 (47.3)	29 (52.7)
Not available	5 (71.4)	2 (28.6)
Pre-treatment CA-125 levels, n (%)			5.141	0.023
Normal	76 (60.8)	49 (39.2)
Abnormal	20 (41.7)	28 (58.3)
Not Available	4 (66.7)	2 (33.3)

B, Excluding 10 patients who received neoadjuvant chemotherapy

Variables	HER2 zero expression	HER2 expression	χ²	P-value

No. of patients	94	75
Vascular or perineural invasion, n (%)			4.751	0.029
Negative	62 (62.6)	37 (37.4)
Positive	32 (45.7)	38 (54.3)
Lymph node metastasis, n (%)			9.979	0.002
Negative	77 (63.1)	45 (36.9)
Positive	17 (36.2)	30 (63.8)
Depth of invasion, n (%)			1.180	0.277
Not infiltrated into deep muscle layer	48 (60.0)	32 (40.0)
Infiltration into the deep muscle layer	46 (51.7)	43 (48.3)
Tumor size, n (%)			0.629	0.428
≤4 cm	69 (53.9)	59 (46.1)
>4 cm	25 (61.0)	16 (39.0)

P-values were calculated using the χ² test, with percentages showing the expression ratio of HER2-positive or HER2-negative patients for each item. CA19-9, carbohydrate antigen 19-9; CA-125, cancer antigen 125; FIGO, International Federation of Gynecology and Obstetrics; HER2, human epidermal growth factor receptor 2.

Table IV.

Expression rates of PD-L1 and HER2.

PD-L1 expression	HER2 expression, n (%)	HER2 zero expression, n (%)	χ²	P-value
Negative	6 (37.5)	10 (62.5)	4.259	0.039
Positive	15 (71.4)	6 (28.6)

PD-L1, PD-L1, programmed death-ligand; HER2, human epidermal growth factor receptor 2.

Table V.

Multivariate analysis of factors associated with disease progression in 179 patients after radical surgery for cervical adenocarcinoma.

Subgroup	HR (95% CI)	P-value
Age, years
≤60	1.000
>60	0.751 (0.313–1.799)	0.520
FIGO stage
I–IIB	1.000
III–IV	1407.350 (0–1.006×10⁵⁵)	0.905
Tumor size, cm
≤4	1.000
>4	1.505 (0.738–3.068)	0.261
Vascular or perineural invasion
Negative	1.000
Positive	0.279 (0.12–0.651)	0.003
Depth of invasion
Not infiltrated into deep muscle layer	1.000
Infiltration into the deep muscle layer	0.592 (0.227–1.544)	0.284
Pre-treatment CA19-9 levels
Normal	1.000
Abnormal	1.161 (0.604–2.231)	0.654
Pre-treatment CA-125 levels
Normal	1.000
Abnormal	1.187 (0.59–2.389)	0.630
HER2 expression status
Negative	1.000
Positive	0.752 (0.386–1.462)	0.401
Lymph node metastasis
Negative	1.000
Positive	0.000 (0–1.937×10⁴⁸)	0.893

CA19-9, carbohydrate antigen 19-9; CA-125, cancer antigen 125; FIGO, International Federation of Gynecology and Obstetrics; HR, hazard ratio; CI, confidence interval; HER2, human epidermal growth factor receptor 2.